Holen Sie sich die Stockscreener-App
2.06
3.74%
-0.08
Handel nachbörslich:
2.05
-0.01
-0.49%
Schlusskurs vom Vortag:
$2.14
Offen:
$2.13
24-Stunden-Volumen:
203.40K
Relative Volume:
0.49
Marktkapitalisierung:
$192.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.60M
KGV:
68.67
EPS:
0.03
Netto-Cashflow:
$-62.91M
1W Leistung:
+15.08%
1M Leistung:
+29.56%
6M Leistung:
+44.06%
1J Leistung:
+13.81%
1-Tages-Spanne:
$2.005
$2.135
1-Wochen-Bereich:
$1.74
$2.31
52-Wochen-Spanne:
$1.13
$2.38
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.06 | 200.17M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-05-13 | Eingeleitet | Stifel | Buy |
| 2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-22 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
| 2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-23 | Fortgesetzt | Jefferies | Buy |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-02-07 | Eingeleitet | MLV & Co | Buy |
| 2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now - AOL.com
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - AOL.com
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings - AOL.com
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Compugen (CGEN) Quarterly Loss Near US$7 Million Tests Bullish Profitability Narrative - simplywall.st
Compugen (CGEN) Q4 2025 Earnings Call Transcript - The Globe and Mail
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Compugen earnings beat by $0.68, revenue topped estimates - Investing.com South Africa
Chegg Earnings: Big Quarter Sends Shares Higher - AOL.com
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN) - Seeking Alpha
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compugen Q4 2025 Earnings Call Transcript - MarketBeat
Compugen Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
What Smart Money Loves About Lilly - AOL.com
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Earnings call transcript: Compugen Q4 2025 sees earnings beat, stock surges - Investing.com Nigeria
CGEN: 2025 saw a cash runway extension, profitability, and global clinical trial progress - TradingView
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CGEN: 2025 saw strong revenue growth, a return to profitability, and extended cash runway into 2029 - TradingView
Compugen: Overview of Fourth Quarter Financial Results - Bitget
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress - TipRanks
Partnership payments lift Compugen (NASDAQ: CGEN) to 2025 profit - Stock Titan
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen stock jumps 5% on fourth quarter earnings beat - Investing.com
Compugen: Q4 Earnings Snapshot - marketscreener.com
Compugen : Corporate Presentation - marketscreener.com
Earnings Breakdown: Compugen Q4 - Benzinga
CGEN: Profitability achieved in 2025, driven by AstraZeneca deal and robust clinical progress - TradingView
Compugen (Nasdaq: CGEN) swings to 2025 profit, extends cash runway to 2029 - Stock Titan
Compugen Reports Fourth Quarter and Full Year 2025 Results - Yahoo Finance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Uncovering Potential: Compugen's Earnings Preview - Benzinga
Compugen Ltd expected to post earnings of 5 cents a shareEarnings Preview - TradingView
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition - AOL.com
Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead O - GuruFocus
MSN Money - MSN
Compugen CEO Highlights COM701 Ovarian Cancer MAIA Trial, AstraZeneca and Gilead Updates at Oppenheimer Conf - Defense World
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% - AOL.com
Compugen at Oppenheimer Conference: Strategic Insights on Partnerships - Investing.com India
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Compass Stock a Buy After Kanen Added 1.6 Million Shares to Its Position? - AOL.com
Analyzing Sana Biotechnology (NASDAQ:SANA) & Compugen (NASDAQ:CGEN) - Defense World
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 - AOL.com
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):